Live Breaking News & Updates on புதியது தொழில்நுட்பம் தொடக்கங்கள்

Stay updated with breaking news from புதியது தொழில்நுட்பம் தொடக்கங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ONL Therapeutics Raises $46.9M in Series B Financing

ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on $46.9m in a Series B financing round.
The round included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round include ONL Therapeutics management, InFocus Capital Partners, ExSight Ventures, the University of Michigan’s Michigan Investment in New Technology Startups (MINTS) program, Western Michigan University’s Biosciences Research & Commercialization Center, and the Capital Community Angels. ....

Ann Arbor , United States , David Zacks , David Esposito , Stellam Robertson , Bill Burns , Michigan University Biosciences Research Commercialization Center , Michigan Capital Network Venture Fund , University Of Michigan Investment , Drug Administration , Capital Community Angels , Jjdc Inc , Onl Therapeutics Inc , Technology Startups , Bios Partners , Johnson Innovation , Kaitai Capital , Infocus Capital Partners , Exsight Ventures , Michigan Investment , New Technology Startups , Western Michigan University , Biosciences Research , Commercialization Center , Capital Community , Alcon Laboratories ,

Ann Arbor eye-drug developer ONL Therapeutics raises $47 million in latest venture capital round

Ann Arbor eye-drug developer ONL Therapeutics raises $47 million in latest venture capital round
Studies to expand into areas such as glaucoma
Funding comes from mix of new and existing investors
Getty Images/iStockphoto
Ann Arbor-based pharmaceutical company ONL Therapeutics Inc. has closed on nearly $47 million in a Series B fundraising round that will further the company s work on developing drugs to protect against several eye conditions that cause blindness.
The investment was led by Fort Worth, Texas-based venture capital firm Bios Partners, with participation from several other new investors including Johnson & Johnson Innovation, Katai Capital and others.
The Series B round also included myriad previous investors such as the University of Michigan s Michigan Investment in New Technology Startups (MINTS) and the Capital Community Angels out of Lansing. ....

Fort Worth , United States , David Esposito , Therapeutics Inc , Technology Startups , University Of Michigan Investment , Capital Community Angels , Ann Arbor Based , Bios Partners , Johnson Innovation , Katai Capital , Michigan Investment , New Technology Startups , கோட்டை மதிப்பு , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் எஸ்போசிட்டோ , சிகிச்சை இன்க் , தொழில்நுட்பம் தொடக்கங்கள் , பல்கலைக்கழகம் ஆஃப் மிச்சிகன் முதலீடு , மூலதனம் சமூக தேவதூதர்கள் , ஆண்டு ஆர்பர் அடிப்படையிலானது , பயாஸ் கூட்டாளர்கள் , ஜான்சன் கண்டுபிடிப்பு , கதை மூலதனம் , மிச்சிகன் முதலீடு , புதியது தொழில்நுட்பம் தொடக்கங்கள் ,

ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications

ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months
December 22, 2020 07:00 ET
| Source:
ONL Therapeutics
ONL Therapeutics
Ann Arbor, Michigan, UNITED STATES
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it closed on $46.9 million in a Series B Preferred Stock financing round. The financing included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that particip ....

United States , David Zacks , David Esposito , Stellam Robertson , Bill Burns , Linda Kemnitz , Michigan University Biosciences Research Commercialization Center , Novartis Institutes For Biomedical Research , Michigan Capital Network Venture Fund , Company Contact , University Of Michigan Investment , Drug Administration , Capital Community Angels , Jjdc Inc , Therapeutics Inc , Technology Startups , Seriesb Preferred Stock , Bios Partners , Johnson Innovation , Kaitai Capital , Infocus Capital Partners , Exsight Ventures , Michigan Investment , New Technology Startups , Western Michigan University , Biosciences Research ,